Synchron Inc. Raises $200 Million to Advance Brain Implants
Synchron Inc. has secured $200 million in funding to further develop brain implants that are inserted through blood vessels, significantly lowering the risks and costs compared to traditional surgical methods. This advancement positions Synchron as a major competitor to Elon Musk’s Neuralink.
Innovative Approach to Brain Implants
Unlike most existing brain implants that require craniotomy, Synchron’s leading device, the Stentrode, is implanted within a blood vessel on the brain's surface. This minimally invasive technique enables the implant to be placed without open surgery, potentially making the procedure more accessible in common hospital settings.
Market Position and Valuation
Following the recent funding round, Synchron’s valuation has approached nearly $1 billion, ranking it second in the brain-implant industry behind Neuralink, which is valued at over $9 billion.
Current Developments in Brain Implant Technology
Several companies are creating brain implants aimed at helping people with disabilities such as paralysis, vision or hearing loss, and limited limb movement. These devices enable users to control computers and other technology using their thoughts. However, none of these implants has yet received regulatory approval for long-term medical or recreational use.
According to Bloomberg, a Synchron spokesperson stated, "We have raised $200 million to continue developing brain implants introduced through the bloodstream, reducing surgery risks and costs."
Author's summary: Synchron Inc.'s blood vessel-implanted brain device offers a less invasive alternative to traditional surgery, advancing technology to aid people with disabilities and competing strongly with Neuralink.